Press

Last patient included in Acarix’s exploratory heart failure study, SEISMO

Acarix AB (publ) today announced that the last patient has been included in the exploratory SEISMO study on a potential heart failure application.

Acarix_PR_HF study 200511 ENG

Acarix PR HR Study 200511 SWE

 

 

About Acarix
Acarix was establish in 2009 and is listed on Nasdaq First North Growth Market. Acarix's CADScor@System uses an advanced sensor placed on the skin above the heart to listen to the sounds of cardiac contraction movement and turbulent flow. It has been designed to be an all-in-on system in the sense that the heart signal will be recorded, processed, and displayed as a patient specific score, the CAD-score, on the device screen.